Top Markets
Coin of the day
TaiRx, Inc. TaiRx, Inc.

TaiRx, Inc.

6580
Rang in Aktien #25843
TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a... TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed to treat and alleviate symptoms of various types of colitis. Beyond its developmental drugs, TaiRx also offers Zelnite, a medication that helps maintain patients' blood selenium levels and supports their immune systems. The company's future endeavors also involve the development of nodal diagnostic devices and innovative antibody-based drugs.
Aktienkurs
$0.40861751
Zuletzt synchronisiert: 2026-08-20
Marktkapitalisierung
$45.81M
Veränderung (1 Tag)
-1.15%
Veränderung (1 Jahr)
-45.04%
Land
TW
Handel TaiRx, Inc. (6580)

Kategorie

Aktien-Split-Historie für TaiRx, Inc. (6580)
Die Aktie TaiRx, Inc. (Symbol: 6580) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 21, 2026 statt.
Eine 6580-Aktie, die vor dem Aug 21, 2026 gekauft wurde, entspricht heute 0 6580-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
1 x3
AU
0 -
CH
0 -
US